BioPharmSignal logoBioPharmSignal

Biotech News

Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026

IRIDEX (IRIX)IRIDEXEarnings

SAN JOSE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third

Related news

ICUSeaStar Medical2026-11-04 13:41 EST

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

OCULOcular Therapeutix2026-11-02 12:00 EST

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

TARSTarsus Pharmaceuticals2026-10-29 20:30 EST

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

TMCITreace Medical Concepts2026-10-23 11:05 EST

Treace to Report Third Quarter 2026 Financial Results on November 6, 2026

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OMOutset Medical2026-10-21 20:05 EST

Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

RXSTRxSight2026-10-20 20:05 EST

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

STXSStereotaxis2026-10-20 11:40 EST

Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026

View all latest news

IRIDEX

Ophthalmic Laser Technology Company Iridex develops, manufactures, and markets laser-based medical systems, delivery devices, and accessories for ophthalmology. Its products are used by eye-care specialists to treat glaucoma, diabetic macular edema, and other retinal diseases. MicroPulse Technology The company's proprietary MicroPulse...

Recent company news

IRIXIRIDEX2026-11-03 21:05 EST

Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026

IRIXIRIDEX2026-10-12 11:00 EST

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

IRIXIRIDEX2026-10-05 11:00 EST

Iridex Completes Relocation of Manufacturing Facility to San Jose, California

IRIXIRIDEX2026-08-18 20:05 EST

Iridex Reports Second Quarter 2026 Financial Results

IRIXIRIDEX2026-08-04 20:05 EST

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

Stock data

Close
0.68 USD
Market cap
20.37M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States